 Press Release Distribution |
 |
- PR Home
- Latest News
- Feeds
- Alerts
- Submit Free Press Release
- Journalist Account
- PRNewswire Distribution
Filter News Show All ResultsNews By Country
News By Tag Personalized Medicine  Related Tags Biotech
Biotechnology Breast Cancer Breast Cancer Awareness Cancer Chemotherapy Conference Diagnostics Genelex Genetics Genomics Healthcare Market Research Molecular Diagnostics Nanotechnology Paclitaxel Personalized Healthcare Pharmacogenomics Point Of Use Workers Compensation
| personalized medicine Latest News+ XML/RSSBy Proove Biosciences Five new doctors and leading pain management clinics in Washington State will begin utilizing Proove Biosciences’ Genetic Testing By Proove Biosciences Proove Biosciences’ Vice President of Research and Development, Ben Arthur, Exhibited Proove’s Capacity to Commercialize Genetic Technology in Optimizing Pain Treatments By Arrowhead Publishers Matthew Zubiller, Decision Management Executive at Mckesson will discuss Understanding the Value of Advanced Diagnostics: Aligning Labs, Clinicians and Payers to Make Better Decisions at the 5th Annual Personalized Medicine Conference By Mercury Healthcare International Concierge Medicine Handbook author, Maria Todd invited to write an article in ThePatient.com, a new German lifestyle magazine about being a concierge medicine patient - how and why she chose her doctor, and what its like to be a patient. By IGDRASOL IGDRASOL will present updates on Cynviloq™, its late clinical stage paclitaxel nanoparticle formulation. By IGDRASOL Sorrento Therapeutics, Inc. ("STI"; SRNE: OB) today announced that it has signed an exclusive option to acquire IGDRASOL, a private company focused on the development of oncologic agents for the treatment of cancers. By IGDRASOL IGDRASOL today announced that the Company’s Chief Scientific Officer, Kouros Motamed, Ph.D., will present at the Breakthroughs in Basic & Translational Cancer Research Conference, February 25th, 2013, Maui, HI. By IGDRASOL IGDRASOL today announced that the Company’s Chief Operating Officer, Larn Hwang, Ph.D., will present at the Tumor Invasion and Metastasis conference, January 21st , 2013, San Diego, CA. By IGDRASOL IGDRASOL today announced that Dr. Vuong Trieu, CEO of IGDRASOL, will discuss an overview of the company and the clinical development program for IG-001: a chemical polymer-bound nanoparticle paclitaxel entering phase III clinical testing. By IGDRASOL Personalization of paclitaxel therapy by combination of next generation nanoparticle paclitaxel and point-of-care therapeutic drug monitoring and biomarker testing. By Cambridge Healthtech Institute CHI’s 2nd Annual Point-of-Care Diagnostics Symposium, February 11-12, 2013, San Francisco, CA By Bio-IT World Next-Gen Technology | Big Data | Personalized Medicine | Bio-ITWorld.com By Biomiga Diagnostics Biomiga Diagnostics announces the development of lateral flow point-of-care Therapeutic Drug Monitoring (TDM) assays for Luteinizing Hormone (LH) and Follicle Stimulating Hormone (FSH). These findings will be presented at the AACR 2012 By Cambridge healthtech Institute CHI confirms new speakers for its keynote session on cancer clinical trials in the era of personalized medicine lead by Roche Holding AG, UCSF Helen Diller Family Comprehensive Cancer Center, and Samuel Oschin Comprehensive Cancer Institute. By Biomiga Diagnostics Biomiga Diagnostics, maker of quantitative point-of-care tests for Therapeutic Drug Monitoring and biomarker testing to promote personalized medicine, today announced it is joining Astia, a global network serving women-led high growth start-ups. By Raybiotech, Inc. RayBiotech, Inc., today announced that it has engaged recognized industry expert, David A. Dodd of RiversEdge BioVentures LLC to work with the Company in the areas of Business Development and Strategic Growth Opportunities. All Press ReleasesBy Proove Biosciences Five new doctors and leading pain management clinics in Washington State will begin utilizing Proove Biosciences’ Genetic Testing By Proove Biosciences Proove Biosciences’ Vice President of Research and Development, Ben Arthur, Exhibited Proove’s Capacity to Commercialize Genetic Technology in Optimizing Pain Treatments By Arrowhead Publishers Matthew Zubiller, Decision Management Executive at Mckesson will discuss Understanding the Value of Advanced Diagnostics: Aligning Labs, Clinicians and Payers to Make Better Decisions at the 5th Annual Personalized Medicine Conference By Proove Biosciences During the April 27th, 2013 National Drug Take Back Day, 387 Pounds of Prescription Medication was Collected and Disposed By Mercury Healthcare International Concierge Medicine Handbook author, Maria Todd invited to write an article in ThePatient.com, a new German lifestyle magazine about being a concierge medicine patient - how and why she chose her doctor, and what its like to be a patient. By Applied Spectral Imaging Inc. Delivering a state-of-the-art integrated computerized analysis instrument and cell enrichment solution By IGDRASOL IGDRASOL will present updates on Cynviloq™, its late clinical stage paclitaxel nanoparticle formulation. By Cypher Genomics Cypher Genomics: Ahead of the Curve A San Diego Company is Poised to Lead the Genome Interpretation Industry SAN DIEGO, C.A., Mar. By IGDRASOL Sorrento Therapeutics, Inc. ("STI"; SRNE: OB) today announced that it has signed an exclusive option to acquire IGDRASOL, a private company focused on the development of oncologic agents for the treatment of cancers. By IGDRASOL IGDRASOL today announced that the Company’s Chief Scientific Officer, Kouros Motamed, Ph.D., will present at the Breakthroughs in Basic & Translational Cancer Research Conference, February 25th, 2013, Maui, HI. By IGDRASOL IGDRASOL today announced that the Company’s Chief Operating Officer, Larn Hwang, Ph.D., will present at the Tumor Invasion and Metastasis conference, January 21st , 2013, San Diego, CA. By IGDRASOL IGDRASOL today announced that Dr. Vuong Trieu, CEO of IGDRASOL, will discuss an overview of the company and the clinical development program for IG-001: a chemical polymer-bound nanoparticle paclitaxel entering phase III clinical testing. By IGDRASOL Personalization of paclitaxel therapy by combination of next generation nanoparticle paclitaxel and point-of-care therapeutic drug monitoring and biomarker testing. By Cambridge Healthtech Institute CHI’s 2nd Annual Point-of-Care Diagnostics Symposium, February 11-12, 2013, San Francisco, CA By Bio-IT World Next-Gen Technology | Big Data | Personalized Medicine | Bio-ITWorld.com By Mary Ann Liebert, Inc., publishers Many biotech observers maintain that the future of healthcare will largely be based on the field of personalized medicine, reports Genetic Engineering & Biotechnology News (GEN). By Arrowhead Publishers & Conferences Arrowhead Publishers & Conferences has just announced a new panel session to take place at their 4th Annual Personalized medicine Conference (Boston, MA, September 12-13, 2012) entitled: The Angel Investor & Venture Capital Perspective By Arrowhead Publishers & Conferences September 12 & 13, hear speakers tackle the issues driving, as well as restraining, the clinical delivery of personalized medicine, including coding and reimbursement, whole genome sequencing, and market access challenges for companion diagnostics. By Cambridge Healthtech Institute A Two Day Event Focusing on the Challenges in eHealth and Personalized Medicine. By Biomiga Diagnostics Biomiga Diagnostics announces the development of lateral flow point-of-care Therapeutic Drug Monitoring (TDM) assays for Luteinizing Hormone (LH) and Follicle Stimulating Hormone (FSH). These findings will be presented at the AACR 2012 By Cambridge healthtech Institute CHI confirms new speakers for its keynote session on cancer clinical trials in the era of personalized medicine lead by Roche Holding AG, UCSF Helen Diller Family Comprehensive Cancer Center, and Samuel Oschin Comprehensive Cancer Institute. By Biomiga Diagnostics Biomiga Diagnostics, maker of quantitative point-of-care tests for Therapeutic Drug Monitoring and biomarker testing to promote personalized medicine, today announced it is joining Astia, a global network serving women-led high growth start-ups. By Genomic Expression Inc Exciting new genomics technology can deliver better treatments for less money - It is estimated that only half of all prescribed medicines work on the individual patient By Raybiotech, Inc. RayBiotech, Inc., today announced that it has engaged recognized industry expert, David A. Dodd of RiversEdge BioVentures LLC to work with the Company in the areas of Business Development and Strategic Growth Opportunities. By GENETWORx GENETWORx has launched a new website to highlight their drug-response DNA testing that helps patients, healthcare professionals and plan sponsors determine the right dose, of the right medication, for the best patient outcome. By Mary Ann Liebert, Inc., publishers The convergence of commercial genomic kits and electronic medical records is helping to drive the healthcare industry’s focus on personalized medicine, reports Genetic Engineering & Biotechnology News (GEN) By Van Andel Institute First-of-its-kind clinical trial to provide new hope for children with advanced cancer receives FDA approval By Cambridge Healthtech Institute Cambridge Healthtech Institute will be hosting the 2nd Annual Companion Diagnostics as an Integral Part of Personalized Medicine Conference in Washington, DC on August 24-25, 2011. This conference is part of CHI’s Next Generation Dx Summit. By Yuko Ueki, Global Information Inc. Global Information Inc. would like to present a new market research report, "Personalized Medicine Market Worldwide (2010-2015): By Segments, Technologies, Opportunities, Challenges & Future Forecast" by Renub Research. By Arrowhead Publishers A new report from Diaceutics for the first time analyzes which drug companies are best prepared to capitalize on new discoveries in genetic biomarkers and translate them into personalized medicine. By Arrowhead Publishers and Conferences Arrowhead Publishers and Conferences will be hosting the 3rd Annual Personalized Medicine Partnerships Conference in Washington, DC on April 11-12, 2011. This conference will shed light on issues of importance to the future of personalized medicine. By Bio-IT World Deadline for submissions is February 4, 2011 By Insight Pharma Reports, a division of CHI Next-Generation Sequencing Spurs Personalized Mitochondrial Medicine Interview Transcript Now Available for Complimentary Download By Arrowhead Publishers and Conferences This conference will shed light on issues of importance to the future of personalized medicine, including the importance of Rx-Dx partnerships, adoption and the commercial realities of personalized medicine in the global healthcare marketplace. By Michele Westergaard Leading Professionals From Pharmaceutical and Biotechnology Companies Examine Advancements in Genomic Research By Arrowhead Publishers and Conferences The era of Personalized Medicine is set to revolutionize the healthcare industry. As our knowledge of genetics and molecular biology rapidly expands, a personalized approach to medical care is becoming increasingly important. By Visionshopsters In his report SNP Genotyping and Analysis Markets he looks at SNP analysis instruments, reagents, and related software and services, providing information critical to having an understanding of the business behind this new technology By Linwright Design The National Center for Policy Analysis Sees Concierge Medicine as the Affordable Answer By National Foundation for Cancer Research, Genelex 30,000 breast cancer survivors taking tamoxifen are being put unnecessarily at risk of a reccurence due to slow adoption of a simple genetic test. By Genelex Corp. The published reports of Mr. Jackson's medications illustrate an important issue- any two drugs may be safe in combination but the cumulative effect of many drugs can be difficult to detect and very dangerous. By Bi-Biomics World-Class Histology that improves pathology diagnosis through better quality. Improved protein preservation and 100X better image detail make slides easier to read and diagnosis more accurate. Research was never so enjoyable as with UltraLight. By Jim Roche NJ We Innovate Healthcare. As a research-focused healthcare company, Roche discovers, develops and provides innovative diagnostic and therapeutic products and services that deliver significant benefits to patients and healthcare professionals – from e Page:
| ||||||||||||||||||||||
Like PRLog?
8.4K1.9K2.6K